Surgical tricuspid valve replacement

Research output: Chapter in Book/Report/Conference proceedingChapter


Tricuspid valve replacement is a high-risk treatment associated with suboptimal results. Emergent clinical status at surgery, advanced age, pulmonary hypertension, and NYHA class III/IV have been identified as predictive risk factors for operative mortality. The operative mortality ranges from 12 to 26 %. For the tricuspid valve replacement, using a mechanical or biological prostheses valve remains a controversial subject. There are no real differences in mortality, morbidity, and rate of reintervention by type of prosthesis implanted. The range of survival at 5 years is 60-72 %, and at 10 years, it is from 42 to 65 %. Freedom from reoperation is about 85 % at 10 years, comparable in the two groups of prosthesis used.

Original languageEnglish
Title of host publicationThe Tricuspid Valve in Congenital Heart Disease
PublisherSpringer-Verlag Italia s.r.l.
Number of pages7
ISBN (Print)9788847054004, 8847053994, 9788847053991
Publication statusPublished - Feb 1 2014

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Surgical tricuspid valve replacement'. Together they form a unique fingerprint.

Cite this